Penumbra, Inc. (NYSE:PEN) CFO Sridhar Kosaraju sold 4,290 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $103.52, for a total transaction of $444,100.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Sridhar Kosaraju also recently made the following trade(s):

  • On Monday, November 20th, Sridhar Kosaraju sold 21,956 shares of Penumbra stock. The shares were sold at an average price of $105.27, for a total transaction of $2,311,308.12.
  • On Wednesday, November 15th, Sridhar Kosaraju sold 10,900 shares of Penumbra stock. The shares were sold at an average price of $105.89, for a total transaction of $1,154,201.00.

Penumbra, Inc. (PEN) opened at $107.55 on Wednesday. Penumbra, Inc. has a 1-year low of $57.85 and a 1-year high of $116.35.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.07. The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $79.17 million. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. Penumbra’s quarterly revenue was up 24.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.04) EPS. sell-side analysts anticipate that Penumbra, Inc. will post -0.15 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/sridhar-kosaraju-sells-4290-shares-of-penumbra-inc-pen-stock/1719201.html.

A number of brokerages have recently issued reports on PEN. Canaccord Genuity boosted their price objective on shares of Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets boosted their price objective on shares of Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Zacks Investment Research raised shares of Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, BidaskClub downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a report on Friday, August 18th.

Institutional investors have recently modified their holdings of the stock. First Trust Advisors LP boosted its holdings in Penumbra by 811.1% in the 2nd quarter. First Trust Advisors LP now owns 22,113 shares of the company’s stock worth $1,940,000 after buying an additional 19,686 shares during the period. Eagle Asset Management Inc. boosted its holdings in Penumbra by 168.7% in the 2nd quarter. Eagle Asset Management Inc. now owns 510,918 shares of the company’s stock worth $44,833,000 after buying an additional 320,794 shares during the period. American Century Companies Inc. bought a new position in Penumbra in the 2nd quarter worth $26,824,000. Vanguard Group Inc. boosted its holdings in Penumbra by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,165,995 shares of the company’s stock worth $190,066,000 after buying an additional 47,768 shares during the period. Finally, State Street Corp boosted its holdings in Penumbra by 8.5% in the 1st quarter. State Street Corp now owns 512,470 shares of the company’s stock worth $42,764,000 after buying an additional 40,271 shares during the period. 72.73% of the stock is owned by institutional investors.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.